A FAIR Data Foundation for AI-Supported Regulatory Decision-Making in Drug and Biological Products
Tags: Artificial Intelligence, Regulatory Compliance, FAIR Data, Life Sciences
AI is rapidly becoming embedded across the pharmaceutical lifecycle, from toxicology prediction and synthetic control arms to safety surveillance and manufacturing decisions. But as AI becomes part of regulated decision-making, governance expectations are rising just as quickly.
In this whitepaper, Colin Wood explores how emerging FDA and EU guidance is reshaping the role of AI in drug and biological product development and why FAIR (Findable, Accessible, Interoperable, Reusable) data principles are becoming essential for long-term traceability, reproducibility, and regulatory trust. Organizations that build FAIR-compliant infrastructure today will move faster, audit cleaner, and submit with confidence tomorrow.
What's Inside
Eight chapters covering
the full governance picture
01
Why the FDA 2025 guidance shifts AI from tool to regulated lifecycle component
02
How AI governance and data governance must be coordinated, not siloed
03
What FDA guidance implies for LLM-driven AI agents and Human-in-the-Loop requirements
04
New opportunities AI agents open for regulatory inspections and dynamic knowledge environments
05
The identifier failure modes that create long-term audit risk, and how to resolve them
06
A step-by-step GUPRI implementation strategy that preserves existing platform identifiers
07
Decision data schema, provenance standards, and Context Graph architecture
08
Full conceptual data model for AI Models, AI Agents, and supporting governance entities
FAQs
Answers to what you're probably
already asking
What is FAIR data and why does it matter for pharmaceutical AI?
FAIR stands for Findable, Accessible, Interoperable, and Reusable. In pharmaceutical AI, FAIR data infrastructure ensures that every AI-influenced decision from a stability prediction to a safety signal can be automatically traced, reconstructed, and audited without manual intervention. The FDA's 2025 guidance and related global frameworks are pushing organizations away from governance-by-documentation and toward machine-readable, introspectable data ecosystems that meet ALCOA+ and 21 CFR Part 11 requirements.
What is a GUPRI, and how is it different from a standard UUID?
A GUPRI is a Globally Unique, Persistent, and Resolvable Identifier. Standard UUIDs and platform-generated IDs are locally unique but typically fail three of the four FAIR requirements: they're not resolvable via standard protocols, not persistent across platform migrations, and not accessible once an asset is archived or deleted. A GUPRI wraps any existing identifier inside a persistent, resolving namespace so it continues to link to metadata and provenance records even years after the original platform is decommissioned.
Does the FDA's 2025 guidance directly address AI agents and LLMs?
The guidance predates the rapid rise of LLM-driven agents and doesn't address them explicitly. However, core principles Credibility Plans, Context of Use, AI Model Risk assessment, and Human-in-the-Loop oversight can and should be extended to the agent level. EU GMP Annex 22 currently discourages generative AI and LLMs in critical GMP applications, though this stance is expected to evolve as explainable, auditable AI systems mature.
Who should read this whitepaper?
This whitepaper is written for senior decision-makers and technical leads in life sciences: Chief Data Officers, Chief AI Officers, Heads of Regulatory Affairs, Quality and Compliance leaders, Data Architects, and R&D Platform teams who are either building AI capabilities or preparing for regulatory scrutiny of existing AI use. The content is strategic but grounded in practical implementation guidance.
What concrete next steps does the whitepaper recommend?
The paper recommends treating FAIR-compliant AI infrastructure as a strategic program, not a side project. Concrete steps include implementing a GUPRI namespace before identifiers become deeply embedded in regulatory data; extending AI governance frameworks to cover AI agents with individual Credibility Plans; adopting provenance standards like PROV-O for decision records; and building Context Graphs that link decisions, evidence, datasets, and AI systems into a queryable, auditable knowledge environment.